Buscar en
Gastroenterología y Hepatología
Toda la web
Inicio Gastroenterología y Hepatología Guía de práctica clínica sobre el manejo del paciente con dispepsia
Información de la revista
Vol. 26. Núm. 9.
Páginas 571-613 (Enero 2003)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 26. Núm. 9.
Páginas 571-613 (Enero 2003)
DOI: 10.1016/S0210-5705(03)70414-2
Acceso a texto completo
Guía de práctica clínica sobre el manejo del paciente con dispepsia
Visitas
...
JJ. Mascorta, M. Marzob, P. Alonso-Coellob, M. Barenysc, F. Carballoc, M. Fernándezb, LJ. Ferrándiza, X. Bonfillb, JM. Piquéc
a Sociedad Española de Medicina de Familia y Comunitaria
b Centro Cochrane Iberoamericano
c Asociación Española de Gastroenterología
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
N.J. Talley, V. Stanghellini, R.C. Heading, K.L. Koch, J.R. Malagelada, G.N. Tytgat.
Functional gastroduodenal disorders.
Gut, 45 (1999), pp. 37-42
[2.]
Institute for Clinical Systems Improvement.
Health Care Guideline.
[3.]
Aymerich M, Baena JM, Boix C, Carrillo R, Madrilejos R, Mascort JJ et al. Direcció clínica en l'atenció primària. Dispepsia - H. pylori. Guies de pràctica clínica i material docent. http://www.gencat.net/ics/professionals/guies/dispepsia/dispepsia.htm
[4.]
L. Agreus.
Natural history of dyspepsia.
Gut, 50 (2002), pp. 2-9
[5.]
Grupo de trabajo de la guía de práctica clínica sobre ERGE. Manejo del paciente con enfermedad por reflujo gastroesofágico (ERGE). Guía de práctica clínica. Barcelona: Asociación Española de Gastroenterología, Sociedad Española de Medicina de Familia y Comunitaria y Centro Cochrane Iberoamericano; 2001 Programa de Elaboración de Guías de Práctica Clínica en Enfermedades Digestivas, desde la Atención Primaria a la Especializada: 1. http://www.guiasgastro.net
[6.]
S.J.O. Veldhuyzen van Zanten, N. Flook, N. Chiba, D. Armstrong, A. Barkun, a.l. Bradette M et.
for the Canadian Dyspepsia Working Group.
An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. CMAJ, 162 (2000), pp. 3-23
[7.]
J.E. Kellow.
Organic causes of dyspepsia, and discriminating functional from organic dyspepsia.
Best Pract Res Clin Gastroenterol, 15 (2001), pp. 477-487
[8.]
R.C. Heading.
Prevalence of upper gastrointestinal symptoms in the general population: a systematic review.
Scand J Gastroenterol Suppl, 231 (1999), pp. 3-8
[9.]
SBU -The Swedish Council on Technology Assessment in Health Care.
Stomach pain -evidence-based methods in the diagnosis and treatment of dyspepsia.
Stockholm, (2000),
[10.]
V. Stanghellini.
Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST).
Scand J Gastroenterol Suppl, 231 (1999), pp. 20-28
[11.]
A.M. Caballero Plasencia, S. Sofos Kontoyannis, J.L. Martín Ruiz, M. Valenzuela Barranco.
La prevalencia de la dispepsia en España.
Med Clin (Barc), 103 (1994), pp. 717
[12.]
M.D. Schwartz.
Dyspepsia, peptic ulcer disease, and esophageal reflux disease.
West J Med, 176 (2002), pp. 98-103
[13.]
J.L. Turabian, V. Gutiérrez.
Variaciones en la frecuencia de las enfermedades crónicas y los factores de riesgo en atención primaria: 1985-1995.
Aten Primaria, 18 (1996), pp. 65-69
[14.]
N.J. Talley.
Dyspepsia: management guidelines for the millennium.
Gut, 50 (2002), pp. 72-78
[15.]
O.V. Bazaldua, F.D. Schneider.
Evaluation and management of dyspepsia.
Am Fam Physician, 60 (1999), pp. 1.773-1.788
[16.]
A. Haycox, T. Einarson, A. Eggleston.
The health economic impact of upper gastrointestinal symptoms in the general population: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST).
Scand J Gastroenterol Suppl, 231 (1999), pp. 38-47
[17.]
N.J. Talley, M.D. Silverstein, L. Agreus, O. Nyren, A. Sonnenberg, G. Holtmann.
AGA technical review: evaluation of dyspepsia. American Gastroenterological Association.
Gastroenterology, 114 (1998), pp. 582-595
[18.]
R.S. Fisher, H.P. Parkman.
Management of non ulcer dyspepsia.
N Engl J Med, 339 (1998), pp. 1.376-1.381
[19.]
M. Barenys, A. Abad, J.M. Pons, V. Moreno, R. Rota, A. Granados, et al.
Scoring system has better discriminative value than Helicobacter pylori testing in patients with dyspepsia in a setting with high prevalence of infection.
Eur J Gastroenterol Hepatol, 12 (2000), pp. 1.275-1.282
[20.]
Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, Version 1.0.IARC Cancer Base n.° 5. Lyon, IARC Press, 2001. Limited version available from: http://www-dep.iarc.fr/globocan/globocan.htm. Last updated on 03/02/2001
[21.]
P. Moayyedi, J. Mason.
Clinical and economic consequences of dyspepsia in the community.
Gut, 50 (2002), pp. 10-12
[22.]
M. Ruiz, F. Vilasante, F. León, V. González-Lara, C. González, M. Crespo, et al.
Cuestionario sobre calidad de vida asociada a dispepsia. Adaptación española y validación del cuestionario Dyspepsia Related Health Scale.
Med Clin (Barc), 117 (2001), pp. 567-573
[23.]
P. Enck, D. Dubois, P. Marquis.
Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST).
Scand J Gastroenterol Suppl, 231 (1999), pp. 48-54
[24.]
K.W. Olden.
Are psychosocial factors of aetiological importance in functional dyspepsia?.
Baillieres Clin Gastroenterol, 12 (1998), pp. 557-571
[25.]
K.W. Olden, D.A. Drossman.
Psychologic and psychiatric aspects of gastrointestinal disease.
Med Clin North Am, 84 (2000), pp. 1.313-1.327
[26.]
L. Kay, T. Jorgensen.
Epidemiology of upper dyspepsia in random population. Prevalence, incidence, natural history and risk factors.
Scan J Gastroenterol, 29 (1994), pp. 1-7
[27.]
L.I. Yuyuan, N.I.E. Yuqiang, S.H.A. Weihong, S.U. Hua.
The link between social psychosocial and functional dyspepsia: An epidemiological study.
Chin Med J, 115 (2002), pp. 1.082-1.084
[28.]
V. Stanghellini.
Relationship between upper gastrointestinal symptoms and lifestyle, psychosocial factors and comorbidity in the general population: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST).
Scand J Gastroenterol Suppl, 231 (1999), pp. 29-37
[29.]
D. Pantoflickova, A.L. Blum, H.R. Koelz.
Helicobacter pylori and functional dyspepsia: a real causal link?.
Bailleres Clin Gastroenterol, 12 (1998), pp. 503-532
[30.]
J. Danesh, M. Lawrence, M. Murphy, S. Roberts, R. Collins.
Systematic review of the epidemiological evidence on Helicobacter pylori infection and nonulcer or uninvestigated dyspepsia.
Arch Intern Med, 160 (2000), pp. 1.192-1.198
[31.]
F. Bazzoli, L. De Luca, P. Pozzato, R.M. Zagari, S. Fossi, L. Ricciardiello, et al.
Helicobacter pylori and functional dyspepsia: review of previous studies and commentary on new data.
Gut, 50 (2002), pp. 33-35
[32.]
G.H. Elta, E.M. Behler, T.J. Colturi.
Comparison of coffee intake and coffee-induced symptoms in patients with duodenal ulcer, nonulcer dyspepsia, and normal controls.
Am J Gastroenterol, 85 (1990), pp. 1.339-1.342
[33.]
S. Nandurkar, N.J. Talley, H. Xia, H. Mitchell, S. Hazel, M. Jones.
Dyspepsia in the community is linked to smoking and aspirin use but not to Helicobacter pylori infection.
Arch Intern Med, 158 (1998), pp. 1.427-1.433
[34.]
M. Woodward, C.E. Morrison, K.e. McColl.
The prevalence of dyspepsia and use of antisecretory medicatioin in North Gasgow: role of Helicobacter pylori vs lifestyle factors.
Aliment Pharmacol, 13 (1999), pp. 1.505-1.509
[35.]
P. Bytzer, S. Howell, M. Leemon, L.J. Young, M.P. Jones, N.J. Talley.
Low socioeconomic class is a risk factor for upper and lower gastrointestinal symptoms: a population based study in 15000 Australian adults.
Gut, 49 (2001), pp. 66-67
[36.]
N.J. Talley, A.L. Weaver, A.R. Zinsmeister.
Smoking, alcohol, and nonsteroidal anti-inflammatory drugs in outpatients with functional dyspepsia and among dyspepsia subgroups.
Am J Gastroenterol, 89 (1994), pp. 524-528
[37.]
N.J. Talley, McNeilD, D.W. Piper.
Environmental factors and chronic unexplained dyspepsia. Association with acetaminophen but not other analgesics, alcohol, coffee, tea, or smoking.
Dig Dis Sci, 33 (1988), pp. 641-648
[38.]
J.H. Kurata, A.N. Nogawa.
Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking.
J Clin Gastroenterol, 24 (1997), pp. 2-17
[39.]
J.Q. Huang, S. Sridhar, R.H. Hunt.
Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis.
[40.]
F.K. Chan, K.F. To, J.C. Wu, M.Y. Yung, W.K. Leung, T. Kwok, et al.
Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal antiinflammatory drugs: a randomised trial.
Lancet, 359 (2002), pp. 9-13
[41.]
W.L. Straus, J.J. Ofman, C. MacLean, S. Morton, M.L. Berger, E.A. Roth, et al.
Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions.
Am J Gastroentrol, 97 (2002), pp. 1.951-1.958
[42.]
C. Aalykke, K. Lauritsen.
Epidemiology of NSAID-related gastroduodenal mucosal injury.
Best Pract Res Clin Gastroenterol, 15 (2001), pp. 705-722
[43.]
The National Prescribing Center.
Managing dyspepsia: the role of Helicobacter pylori.
MeReC Bulletin, 12 (2001), pp. 1-4
[44.]
P. Moayyedi, A.T. Axon, R. Feltbower, S. Duffett, W. Crocombe, D. Braunholtz, et al.
Relation of adult lifestiles and socioeconomic factors to the prevalence of Helicobacter pylori infection.
Int J Epidemiol, 31 (2002), pp. 624-631
[45.]
R.D. Goodwin, B.S. Murray.
Generalized Anxiety disorder and peptic ulcer disease among adults in the United States.
Psychosomatic Medicine, 64 (2002), pp. 862-866
[46.]
I.B. Andersen, T. Jorgensen, O. Bonnevie, M. Gronbaek, T.I. Sorensen.
Smoking and alcohol intake as risk factors for bleeding and perforated peptic ulcers: a population-based cohort study.
Epidemiology, 11 (2000), pp. 434-439
[47.]
International Agency for Research on Cancer.
Infection with Helicobacter pylori.
IARC Monogr Eval Carcinog Risks Hum, 61 (1994), pp. 177-240
[48.]
P. Correa.
Gastric neoplasia.
Curr Gastroenterol Rep, 4 (2002), pp. 463-470
[49.]
W.M. Priebe, L.R. DaCosta, I.T. Beck.
Is epigastric tenderness a sign of peptic ulcer disease?.
Gastroenterology, 82 (1982), pp. 16-19
[50.]
M.E. Numans, Y. Van der Graaf, N.J. de Wit, F. Touw-Otten, R.A. de Melker.
How much ulcer is ulcer-like? Diagnostic determinants of peptic ulcer in open access gastroscopy.
Fam Pract, 11 (1994), pp. 382-388
[51.]
T. Johannessen, H. Petersen, P.M. Kleveland, J.H. Dybdahl, A.K. Sandvik, E. Brenna, et al.
The predictive value of history in dyspepsia.
Scand J Gastroenterol, 25 (1990), pp. 689-697
[52.]
J.W. Muris, R. Starmans, P. Pop, H.F. Crebolder, J.A. Knottnerus.
Discriminant value of symptoms in patients with dyspepsia.
J Fam Pract, 38 (1994), pp. 139-143
[53.]
P. Bytzer, J.M. Hansen, T. Havelund, A. Malchow-Moller, O.B. Schaffalitzky de Muckadell.
Predicting endoscopic diagnosis in the dyspeptic patient: the value of clinical judgement.
Eur J Gastroenterol Hepatol, 8 (1996), pp. 359-363
[54.]
J.M. Hansen, P. Bytzer, O.B. Schaffalitzky De Muckadell.
Management of dyspeptic patients in primary care. Value of the unaided clinical diagnosis and of dyspepsia subgrouping.
Scand J Gastroenterol, 33 (1998), pp. 799-805
[55.]
M. Bustamante, M.J. Ferrando, F. Devesa, A. Borghol.
Predicción del diagnóstico endoscópico en el paciente con dispepsia: valor del síntoma predominante de presentación y de la presunción clínica inicial.
Gastroenterol Hepatol, 23 (2000), pp. 66-70
[56.]
M. Heikkinen, P. Pikkarainen, M. Eskelinen, R. Julkunen.
GPs’ ability to diagnose dyspepsia based only on physical examination and patient history.
Scand J Prim Health Care, 18 (2000), pp. 99-104
[57.]
Danish dyspepsia study group.
Value of the unaided clinical diagnosis in dyspeptic patients in primary care.
Am J Gastroenterol, 96 (2001), pp. 1.417-1.421
[58.]
R.C. Heading, E. Wager, P.J. Tooley.
Reliability of symptom assessment in dyspepsia.
Eur J Gastroenterol Hepatol, 9 (1997), pp. 779-781
[59.]
J.I. Westbrook, J.H. McIntosh, J.M. Duggan.
Accuracy of provisional diagnoses of dyspepsia in patients undergoing first endoscopy.
Gastrointest Endosc, 53 (2001), pp. 283-288
[60.]
M. Barenys, R. Rota, V. Moreno, R. Villafafila, I. García-Bayo, A. Abad, et al.
Validación prospectiva de un modelo clínico predictivo de dispepsia orgánica en el ámbito de la atención primaria y de las consultas de gastroenterología (Abstract).
astroenterol Hepatol, 26 (2003), pp. 103
[61.]
N.J. Talley, A.L. Weaver, D.L. Tesmer, A.R. Zinsmeister.
Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy.
Gastroenterology, 105 (1993), pp. 1.378-1.386
[62.]
N.J. Talley, A.R. Zinsmeister, C.D. Schleck, L.J. Melton 3rd.
Dyspepsia and dyspepsia subgroups: a population-based study.
Gastroenterology, 102 (1992), pp. 1.259-1.268
[63.]
L. Agreus, K. Svardsudd, O. Nyren, G. Tibblin.
Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time.
Gastroenterology, 109 (1995), pp. 671-680
[64.]
G. Holtmann, V. Stanghellini, N.J. Talley.
Nomenclature of dyspepsia, dyspepsia subgroups and functional dyspepsia: clarifying the concepts.
Baillieres Clin Gastroenterol, 12 (1998), pp. 417-433
[65.]
P.T. Hession, J. Malagelada.
Review article: the initial management of uninvestigated dyspepsia in younger patients-the value of symptom-guided strategies should be reconsidered.
Aliment Pharmacol Ther, 14 (2000), pp. 379-388
[66.]
L.G. Madsen, P. Bytzer.
The value of alarm features in identifying organic causes of dyspepsia.
Can J Gastroenterol, 14 (2000), pp. 713-720
[67.]
Scottish Intercollegiate Guideline Network (SIGN). Dyspepsia. Edimburgh: SIGN, 2003 [en prensa]
[68.]
Alberta Clinical Practice Guideline Working Group. Guideline for Diagnosis and Treatment of Chronic Undiagnosed Dyspepsia in Adults. The Alberta Clinical Guideline Program. June, 2000
[69.]
Bristish Gastroenterology Society.
Dyspepsia Management Guidelines.
[70.]
R.P. Adang, A.W. Ambergen, J.L. Talmon, A. Hasman, J.F. Vismans, R.W. Stockbrugger.
The discriminative value of patient characteristics and dyspeptic symptoms for upper gastrointestinal endoscopic findings: a study on the clinical presentation of 1,147 patients.
Digestion, 57 (1996), pp. 118-134
[71.]
M.B. Wallace, V.L. Durkalski, J. Vaughan, Y.Y. Palesch, E.D. Libby, P.S. Jowell, et al.
Age and alarm symptoms do not predict endoscopic findings among patients with dyspepsia: a multicentre database study.
Gut, 49 (2001), pp. 29-34
[72.]
B. Williams, M. Luckas, J.H. Ellingham, A. Dain, A.C. Wicks.
Do young patients with dyspepsia need investigation?.
Lancet, 2 (1988), pp. 1.349-1.351
[73.]
J. Christie, N.A. Shepherd, B.W. Codling, R.M. Valori.
Gastric cancer below the age of 55: implications for screening patients with uncomplicated dyspepsia.
Gut, 41 (1997), pp. 513-517
[74.]
D. Gillen, K.E. McColl.
Does concern about missing malignancy justify endoscopy in uncomplicated dyspepsia in patients aged less than 55?.
Am J Gastroenterol, 94 (1999), pp. 75-79
[75.]
A. Heaney, J.S. Collins, T.C. Tham, P.R. Watson, J.R. McFarland, K.B. Bamford.
A prospective study of the management of the young Helicobacter pylori negative dyspeptic patientcan gastroscopies be saved in clinical practice?.
Eur J Gastroenterol Hepatol, 10 (1998), pp. 953-956
[76.]
C. Canga 3rd, N. Vakil.
Upper GI malignancy, uncomplicated dyspepsia, and the age threshold for early endoscopy.
Am J Gastroenterol, 97 (2002), pp. 600-603
[77.]
American Gastroenterological Association medical position statement: evaluation of dyspepsia.
Gastroenterology, 114 (1998), pp. 579-581
[78.]
P. Malfertheiner, F. Megraud, C. O’Morain, A.P. Hungin, R. Jones, A. Axon, et al.
The European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection -the Maastricht 2-2000 Consensus Report.
Aliment Pharmacol Ther, 16 (2002), pp. 167-180
[79.]
J.J. Ofman, L. Rabeneck.
The effectiveness of endoscopy in the management of dyspepsia: a qualitative systematic review.
Am J Med, 106 (1999), pp. 335-346
[80.]
F. Cardin, M. Zorzi, A. Furlanetto, C. Guerra, F. Bandini, D. Polito, et al.
Are dyspepsia management guidelines coherent with primary care practice?.
Scand J Gastroenterol, 37 (2002), pp. 1.269-1.275
[81.]
M.T. Hallissey, W.H. Allum, A.J. Jewkes, D.J. Ellis, J.W. Fielding.
Early detection of gastric cancer.
BMJ, 301 (1990), pp. 513-515
[82.]
H.M. Sue-Ling, D. Johnston, I.G. Martin, M.F. Dixon, M.R. Lansdown, M.J. McMahon, et al.
Gastric cancer: a curable disease in Britain.
BMJ, 307 (1993), pp. 591-596
[83.]
M. Bustamante, F. Devesa, A. Borghol, M.J. Fernando.
Influencia de la edad en el diagnóstico endoscópico de los pacientes con dispepsia no complicada.
Rev Sdad Valenciana Patol Dig, 20 (2001), pp. 1-6
[84.]
N.P. Breslin, A.B. Thomson, R.J. Bailey, P.K. Blustein, J. Meddings, E. Lalor, et al.
Gastric cancer and other endoscopic diagnoses in patients with benign dyspepsia.
Gut, 46 (2000), pp. 93-97
[85.]
I.G. Martin, S. Young, H.M. Sue-Ling, D. Johnston.
Delays in the diagnosis of oesophagogastric cancer: a consecutive case series.
BMJ, 314 (1997), pp. 467-470
[86.]
S.M. Griffin, S.A. Raimes.
Proton pump inhibitors may mask early gastric cancer. Dyspeptic patients over 45 should undergo endoscopy before thesedrugs are started.
BMJ, 317 (1998), pp. 1.606-1.607
[87.]
Z. Suvakovic, M.G. Bramble, R. Jones, C. Wilson, N. Idle, J. Ryott.
Improving the detection rate of early gastric cancer requires more than open access gastroscopy: a five year study.
Gut, 41 (1997), pp. 308-313
[88.]
M.G. Bramble, Z. Suvakovic, A.P. Hungin.
Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy.
Gut, 46 (2000), pp. 464-467
[89.]
A.T. Lassen, F.M. Pedersen, P. Bytzer, O.B. Schaffalitzky de Muckadell.
Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial.
Lancet, 356 (2000), pp. 455-460
[90.]
R.J. Laheij, J.L. Severens, E.H. Van de Lisdonk, A.L. Verbeek, J.B. Jansen.
Randomized controlled trial of omeprazole or endoscopy in patients with persistent dyspepsia: a cost-effectiveness analysis.
Aliment Pharmacol Ther, 12 (1998), pp. 1.249-1.256
[91.]
J.M. Pajares.
Helicobacter pylori infection and gastric cancer in Spain.
Hepatogastroenterology, 48 (2001), pp. 1.556-1.559
[92.]
NHS Executive Referral Guidelines for Suspected Cancer.
[93.]
W.H. Allum, S.M. Griffin, A. Watson, D. Colin-Jones.
Guidelines for the management of oesophageal and gastric cancer.
Gut, (2002), pp. 1-23
[94.]
M.J. Buckley, C. Scanlon, P. McGurgan, C.A. O'Morain.
A validated dyspepsia symptom score.
Ital J Gastroenterol Hepatol, 29 (1997), pp. 495-500
[95.]
M.A. Mendall, R.P. Jazrawi, J.M. Marrero, N. Molineaux, J. Levi, J.D. Maxwell, et al.
Serology for Helicobacter pylori compared with symptom questionnaires in screening before direct access endoscopy.
Gut, 36 (1995), pp. 330-333
[96.]
P. Bytzer, J.M. Hansen, O.B. Schaffalitzky de Muckadell, A. Malchow-Moller.
Predicting endoscopic diagnosis in the dyspeptic patient. The value of predictive score models.
Scand J Gastroenterol, 32 (1997), pp. 118-125
[97.]
J.M. Coelho-Filho, J.W. Lima, G.B. Furtado, A. Castelo.
Development of a strategy to optimize the indications for the upper gastrointestinal endoscopy in patients with dyspepsia at the primary care level.
Rev Assoc Med Bras, 46 (2000), pp. 30-38
[98.]
C. Martín de Argila, D. Boixeda, R. Canton, N. Mir, L. de Rafael, J. Gisbert, et al.
Helicobacter pylori infection in a healthy population in Spain.
Eur J Gastroenterol Hepatol, 8 (1996), pp. 1.165-1.168
[99.]
G. Cilla, E. Pérez-Trallero, M. García-Bengoechea, J.M. Marimón, J.I. Arenas.
Helicobacter pylori infection: a seroepidemiological study in Gipuzkoa, Basque Country, Spain.
Eur J Epidemiol, 13 (1997), pp. 945-949
[100.]
A.M. Caballero, S. Kotoyannis, M. Valenzuela, F.J. Casado, J. Guilarte.
Epidemiología de la dispepsia en una población aleatoria mediterránea. Prevalencia de la infección por Helicobacter pylori.
Rev Esp Enferm Dig, 92 (2000), pp. 781-792
[101.]
M. García, J. Martí, I. León, D. Muñiz, J. Teruel, J.M. Baena, et al.
Prevalencia de la infección por Helicobacter pylori en atención primaria: estudio seroepidemiológico.
Aten Primaria, 29 (2002), pp. 553-557
[102.]
D.T. Smoot, M.F. Go, B. Cryer.
Peptic ulcer disease.
Prim Care, 28 (2001), pp. 487-503
[103.]
K. Bodger, M.J. Daly, R.V. Heatley.
Prescribing patterns for dyspepsia in primary care: a prospective study of selected general practitioners.
Aliment Pharmacol Ther, 10 (1996), pp. 889-895
[104.]
B.H. Folkersen, B. Larsen, P. Qvist.
General practitioners’ handling of patients with dyspepsia.
Ugeskr Laeger, 159 (1997), pp. 3.777-3.781
[105.]
G. Martínez-Sánchez, E. Saperas, J. Benavent, F. Mearin, J.L. Pinol, M. Barenys, et al.
Actitud de los médicos de atención primaria del área metropolitana de Barcelona frente al diagnóstico y tratamiento de la infección por Helicobacter pylori en enfermedades gastroduodenales.
Gastroenterol Hepatol, 21 (1998), pp. 473-478
[106.]
E. Gené, X. Calvet, R. Azagra, T. López, M.J. Cubells.
Manejo de la dispepsia, la enfermedad ulcerosa y la infección por Helicobacter pylori en atención primaria.
Aten Primaria, 29 (2002), pp. 486-494
[107.]
C.F. Weijnen, N.J. de Wit, M.E. Numans, A.O. Quartero, T.J. Verheij.
Dyspepsia management in primary care in the Netherlands: to what extent is Helicobacter pylori diagnosis and treatment incorporated? Results from a survey among general practitioners in the Netherlands.
Digestion, 64 (2001), pp. 40-45
[108.]
V. Meineche-Schmidt, G. Fly.
Helicobacter pylori test-and-treat strategy in dyspepsia patients in general practice Too many patients to treat?.
Gut, 43 (1999), pp. A355
[109.]
B. Delaney, P. Moayyedi, J. Deeks, M. Innes, S. Soo, P. Barton, et al.
The management of dyspepsia: a systematic review.
Health Technol Assess, 4 (2000),
[110.]
Delaney BC, Innes MA, Deeks J, Wilson S, Cooner MK, Moayyedi P et al. Initial management strategies for dyspepsia (Cochrane Review). En: The Cochrane Library, n.° 3, 2002. Oxford: Update Software
[111.]
B.M. Spiegel, N.B. Vakil, J.J. Ofman.
Dyspepsia management in primary care: a decision analysis of competing strategies.
Gastroenterology, 122 (2002), pp. 1.270-1.285
[112.]
National Institute for Clinical Excellence.
Guidance on the use of proton pump inhibitors (PPI) in the treatment of dyspepsia. Londres: National Institute for Clinical. Excellence (NICE).
Technology Appraisal, (2000),
[113.]
A.O. Quartero, M.E. Numans, R.A. de Melker, A.W. Hoes, N.J. de Wit.
Dyspepsia in primary care: acid suppression as effective as prokinetic therapy. A randomized clinical trial.
Scand J Gastroenterol, 36 (2001), pp. 942-947
[114.]
S. Ghosh, M. Kinnear.
Dyspepsia in primary care to prescribe or to investigate?.
Br J Gen Pract, 51 (2001), pp. 612-614
[115.]
P.T. Hession, J. Malagelada.
Review article: the initial management of uninvestigated dyspepsia in younger patients -the value of symptom-guided strategies should be reconsidered.
Aliment Pharmacol Ther, 14 (2000), pp. 379-388
[116.]
N.T. Lewin van den Broek, M.E. Numans, E. Buskens, T.J. Verheij, N.J. de Wit, A.J. Smout.
A randomised controlled trial of four management strategies for dyspepsia: relationships between symptom subgroups and strategy outcome.
Br J Gen Pract, 51 (2001), pp. 619-624
[117.]
J.J. Ofman, L. Rabeneck.
The effectiveness of endoscopy in the management of dyspepsia: a qualitative systematic review.
Am J Med, 106 (1999), pp. 335-346
[118.]
L. Rabeneck, J. Souchek, K. Wristers, T. Menke, E. Ambriz, I. Huang, et al.
A double blind, randomized, placebo-controlled trial of proton pump inhibitor therapy in patients with uninvestigated dyspepsia.
Am J Gastroenterol, 97 (2002), pp. 3.045-3.051
[119.]
R. Brignoli, P. Watkins, F. Halter.
The Omega-Project -a comparison of two diagnostic strategies for risk -and cost-oriented management of dyspepsia.
Eur J Gastroenterol Hepatol, 9 (1997), pp. 337-343
[120.]
J.P. Gisbert, J.M. Pajares.
Helicobacter pylori “test-and-scope™ strategy for dyspeptic patients.
Helicobacter, 2 (2000), pp. 57-68
[121.]
G.M. Sobala, J.E. Crabtree, J.A. Pentith, B.J. Rathbone, T.M. Shallcross, J.I. Wyatt, et al.
Screening dyspepsia by serology to Helicobacter pylori.
Lancet, 338 (1991), pp. 94-96
[122.]
P. Patel, S. Khulusi, M.A. Mendall, R. Lloyd, R. Jazrawi, J.D. Maxwell, et al.
Prospective screening of dyspeptic patients by Helicobacter pylori serology.
Lancet, 346 (1995), pp. 1.315-1.318
[123.]
B.C. Delaney, S. Wilson, A. Roalfe, L. Roberts, V. Redman, A. Wearn, et al.
Randomised controlled trial of Helicobacter pylori testing and endoscopy for dyspepsia in primary care.
BMJ, 322 (2001), pp. 898-901
[124.]
G. Rubin, V. Meineche-Schmidt, A. Roberts, N. de Wit.
The use of consensus to develop guidelines for the management of Helicobacter pylori infection in primary care.
Fam Pract, 17 (2000), pp. 21-26
[125.]
The European Helicobacter Study Group.
Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report.
Gut, 41 (1997), pp. 8-13
[126.]
R. Jones, C. Tait, G. Sladen, J. Weston-Baker.
A trial of a testand-treat strategy for Helicobacter pylori positive dyspeptic patients in general practice.
Int J Clin Pract, 53 (1999), pp. 413-416
[127.]
A. Heaney, J.S. Collins, R.G. Watson, R.J. McFarland, K.B. Bamford, T.C. Tham.
A prospective randomised trial of a "test and treat" policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic.
Gut, 45 (1999), pp. 186-190
[128.]
K.E. McColl, L.S. Murray, D. Gillen, A. Walker, A. Wirz, J. Fletcher, et al.
Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H. pylori testing alone in the management of dyspepsia.
BMJ, 324 (2002), pp. 999-1.002
[129.]
J.P. Gisbert, J.M. Pajares.
Helicobacter pylori “test-and-treat™ strategy for dyspeptic patients.
Scand J Gastroenterol, 7 (1999), pp. 644-652
[130.]
A.J. Morris, C.F. Craig, C. Morran, H. Burns, K. Harden, A. Power, et al.
The influence of H. pylori status on symptoms and quality of life in patients receiving maintenance acid suppression therapy.
UEGW. Amsterdam, (2001),
[131.]
N. Chiba, S.J. Van Zanten, P. Sinclair, R.A. Ferguson, S. Escobedo, E. Grace.
Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dys-pepsia empiric treatment -Helicobacter pylori positive (CADETHp) randomised controlled trial.
BMJ, 324 (2002), pp. 1.012-1.016
[132.]
Scottish Intercollegiate Guideline Network (SIGN). UPDATE H.
pylori: eradication therapy in dyspeptic disease.
[133.]
N.J. De Wit, A.O. Quartero, M.E. Numans.
Helicobacter pylori treatment instead of maintenance therapy for peptic ulcer disease: the effectiveness of case-finding in general practice.
Aliment Pharmacol Ther, 13 (1999), pp. 1.317-1.321
[134.]
Z. Khan, P. Nair, C. O'Shea, N. Spiers, R.J. Playford, A.C. Wicks.
Does Helicobacter pylori eradication reduce the long-term requirements for acid suppressants in patients with a history of peptic ulcer disease in general practice? Results from a four-year longitudinal study.
Scand J Gastroenterol, 37 (2002), pp. 144-147
[135.]
V. Meineche-Schmidt, G. Rubin, N.J. de Wit.
Helicobacter pylori infection: a comparative review of existing management guidelines.
Fam Pract, 17 (2000), pp. 2-5
[136.]
C.F. Weijnen, M.E. Numans, N.J. de Wit, A.J. Smout, K.G. Moons, T.J. Verheij, et al.
Testing for Helicobacter pylori in dyspeptic patients suspected of peptic ulcer disease in primary care: cross sectional study.
BMJ, 323 (2001), pp. 71-75
[137.]
H. Kolk, H.I. Maaroos, I. Kull, K. Labotkin, K. Loivukene, M. Mikelsaar.
Open access endoscopy in an epidemiological situation of high prevalence of Helicobacter pylori infection: applicability of the guidelines of the European Society for Primary Care Gastroenterology.
Fam Pract, 19 (2002), pp. 231-235
[138.]
R.F. Harvey, R.W. Spence, J.A. Lane, P. Nair, L.J. Murray, I.M. Harvey, et al.
Relationship between the birth cohort pattern of Helicobacter pylori infection and the epidemiology of duodenal ulcer.
QJM, 95 (2002), pp. 519-525
[139.]
Management of upper dyspepsia in general practice (funded by DACEHTA). Primary Research (project). Danish Centre for Evaluation and Health Technology Assessment (DACEHTA). http://www.dihta.dk/projekter/230_uk.asp
[140.]
Gisbert JP, Khorrami, S Badia X, Pajares JM. La estrategia “test and treat™ (diagnosticar y tratar la infección por Helicobacter pylori) ante el paciente dispéptico en Atención Primaria. Club Español para el estudio del Helicobacter pylori. http://www.sepd.org/gaceta/hpclub.htm
[141.]
P. Bytzer, J.M. Hansen, O.B. Schaffalitzky de Muckadell.
Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia.
Lancet, 343 (1994), pp. 811-816
[142.]
B.C. Delaney, S. Wilson, A. Roalfe, L. Roberts, V. Redman, A. Wearn, et al.
Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: a randomised controlled trial in primary care.
Lancet, 356 (2000), pp. 1.965-1.969
[143.]
J.K. Marshall, D. Armstrong, B.J. O'Brien.
Test and treat strategies for Helicobacter pylori in uninvestigated dyspepsia: a Canadian economic analysis.
Can J Gastroenterol, 14 (2000), pp. 379-388
[144.]
A.H. Briggs, M.J. Sculpher, R.P. Logan, J. Aldous, M.E. Ramsay, J.H. Baron.
Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age.
BMJ, 312 (1996), pp. 1321-1325
[145.]
P. Moayyedi, J. Mason, A. Zilles, A.T.R. Axon, D.M. Chalmers, M.F. Drummond.
Screening and treating for H. pylori-Is it costeffective in clinical practice.
Digestion, 59 (1998), pp. 10
[146.]
A. Sonnenberg.
What to do about Helicobacter pylori? A decision analysis of its implication on public health.
Helicobacter, 7 (2002), pp. 60-66
[147.]
M.H. Ebell, L. Warbasse, C. Brenner.
Evaluation of the dyspeptic patient: a cost-utility study.
J Fam Pract, 44 (1997), pp. 545-555
[148.]
P. Moayyedi.
Helicobacter pylori test and treat strategy for young dyspeptic patients: new data.
Gut, 50 (2002), pp. 47-50
[149.]
A. García-Altés, R. Rota, M. Barenys, A. Abad.
“Test and treat™ and endoscopy are the most cost-effective strategies for the management of dyspepsia depending on the age of the patient. 18th Annual Meeting of the International Society of Technology Assessment in Health Care. ISTAHC.
Berlín, (2002),
[150.]
C.P. Dooley, A.W. Larson, N.H. Stace, I.G. Renner, J.E. Valenzuela, J. Eliasoph, et al.
Double-contrast barium meal and upper gastrointestinal endoscopy. A comparative study.
Ann Intern Med, 101 (1984), pp. 538-545
[151.]
J.M. Galloway, J. Gibson, J. Dalrymple.
Endoscopy in primary care: a survey of current practice.
Br J Gen Pract, 52 (2002), pp. 536-538
[152.]
P.C. Shaw, L.K. van Romunde, G. Griffioen, A.R. Janssens, J. Kreuning, G.A. Eilers.
Peptic ulcer and gastric carcinoma: diagnosis with biphasic radiography compared with fiberoptic endoscopy.
[153.]
P.C. Shaw, I.K.I. Romunde, G. Griffioen, A.R. Janssens, J. Kreuning, C.B.H.W. Lamers.
Detection of gastric erosions: comparison of biphasic radiography with fiberoptic endoscopy.
[154.]
RCR Working Party.
Making the best use of a Department of Clinical Radiology, 4.a ed.
[155.]
R.P. Logan, M.M. Walker.
ABC of the upper gastrointestinal tract: epidemiology and diagnosis of Helicobacter pylori infection.
BMJ, 323 (2001), pp. 920-922
[156.]
L.N. Meurer, D.J. Bower.
Management of Helicobacter pylori infection.
Am Fam Physician, 65 (2002), pp. 1.327-1.336
[157.]
A.P. Roberts, S.M. Childs, G. Rubin, N.J. de Wit.
Tests for Helicobacter pylori infection: a critical appraisal from primary care.
Fam Pract, 17 (2000), pp. 12-20
[158.]
C.T. Loy, L.M. Irwig, P.H. Katelaris, N.J. Talley.
Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis.
Am J Gastroenterol, 91 (1996), pp. 1.138-1.144
[159.]
M. Stevens, S. Livsey, R. Swann.
Evaluation of sixteen EIAs for the detection of antibodies to Helicobacter pylori.
pp. 1-46
[160.]
R.J. Laheij, H. Straatman, J.B. Jansen, A.L. Verbeek.
Evaluation of commercially available Helicobacter pylori serology kits: a review.
J Clin Microbiol, 36 (1998), pp. 2.803-2.809
[161.]
D. Vaira, N. Vakil.
Blood, urine, stool, breath, money, and Helicobacter pylori.
Gut, 48 (2001), pp. 287
[162.]
J.P. Gisbert, J.M. Pajares.
Serología “rápida™ para el diagnóstico de la infección por H. Pylori, ¿puede recomendarse su empleo sistemático en la práctica clínica?.
Med Clin (Barc), 118 (2002), pp. 196-197
[163.]
J.P. Gisbert, J.M. Pajares.
Diagnosis of Helicobacter pylori infection by stool antigen determination: a systematic review.
Am J Gastroenterol, 96 (2001), pp. 2.829-2.838
[164.]
N. Vakil, D. Rhew, A. Soll, J.J. Ofman.
The cost-effectiveness of diagnostic testing strategies for H. pylori.
Am J Gastroenterol, 95 (2000), pp. 1.691-1.698
[165.]
V. Savarino, G. Bisso, M. Pivari, P. Zentilin, C. Bilardi, P. Dulbecco, et al.
Effect of gastric acid suppression on 13C-urea breath test: comparison of ranitidine with omeprazole.
Aliment Pharmacol Ther, 14 (2000), pp. 291-297
[166.]
V. Savarino, D. Tracci, P. Dulbecco, M.R. Mele, P. Zentilin, C. Mansi, et al.
Negative effect of ranitidine on the results of urea breath test for the diagnosis of Helicobacter pylori.
Am J Gastroenterol, 96 (2001), pp. 348-352
[167.]
S.J. Connor, F. Seow, M.C. Ngu, P.H. Katelaris.
The effect of dosing with omeprazole on the accuracy of the 13C-urea breath test in Helicobacter pylori-infected subjects.
Aliment Pharmacol Ther, 13 (1999), pp. 1.287-1.293
[168.]
S.J. Connor, M.C. Ngu, P.H. Katelaris.
The impact of short-term ranitidine use on the precision of the 13C-urea breath test in subjects infected with Helicobacter pylori.
Eur J Gastroenterol Hepatol, 11 (1999), pp. 1.135-1.138
[169.]
L. Laine, R. Estrada, M. Trujillo, K. Knigge, M.B. Fennerty.
Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori.
Ann Intern Med, 129 (1998), pp. 547-550
[170.]
J.P. Gisbert, M.M. Cabrera, J.M. Pajares.
Detección del antígeno de Helicobacter pylori en heces para el diagnóstico inicial de la infección y para la confirmación de su erradicación tras el tratamiento.
Med Clin (Barc), 118 (2002), pp. 401-404
[171.]
M.J. Schmulson, E.A. Mayer.
Gastrointestinal sensory abnormalities in functional dyspepsia.
Baillieres Clin Gastroenterol, 12 (1998), pp. 545-556
[172.]
J.R. Malagelada.
Functional dyspepsia. Insights on mechanisms and management strategies.
Gastroenterol Clin North Am, 25 (1996), pp. 103-112
[173.]
Soo S, Moayyedi P, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia (Cochrane Review). En: The Cochrane Library, n.° 3, 2002. Oxford: Update Software
[174.]
F.S. Finney, N. Kinnersley, M. Hughes, C.G. O’Bryan-Tear, J. Lothian.
Meta-analysis of antisecretory and gastrokineticcompounds in functional dyspepsia.
J Clin Gastroenterol, 26 (1998), pp. 312-320
[175.]
H.D. Allescher, A. Bockenhoff, G. Knapp, M. Wienbeck, J. Hartung.
Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies.
Scand J Gastroenterol, 36 (2001), pp. 934-941
[176.]
H.A. Redstone, N. Barrowman, S.J. Veldhuyzen Van Zanten.
H2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials.
Aliment Pharmacol Ther, 15 (2001), pp. 1.291-1.299
[177.]
J.Y. Shiau, K. Vijay, B. Shula, C. Dubé.
The efficacy of proton pump inhibitors in adults with functional dyspepsia.
[178.]
N.J. Talley, K. Lauritsen.
The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies.
Gut, 50 (2002), pp. 36-41
[179.]
A.L. Blum, R. Arnold, M. Stolte, M. Fischer, H.R. Koelz.
The Frosch Study Group. Short course acid suppesive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status.
Gut, 47 (2000), pp. 473-480
[180.]
V.K. Shukla, N. Otten, C. Dubé, D. Moher.
Use of cisapride in patients with non-ulcer dyspepsia: a meta-analysis of randomized trials.
[181.]
J.O. Sander, S.J.O. Veldhuyzen van Zanten, M.J. Jones, M. Verlinden, N.J. Talley.
Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis.
Am J Gastroenterol, 96 (2001), pp. 689-696
[182.]
Cisaprida for non ulcer dyspepsia.
Bandolier, (2000), pp. 76-173
[183.]
V. Arienti, G.R. Corazza, M. Sorge, L. Boriani, F. Ugenti, F. Biagi, et al.
The effects of levosulpiride on gastric and gall-bladder emptying in functional dyspepsia.
Aliment Pharmacol Ther, 8 (1994), pp. 631-638
[184.]
G.R. Corazza, F. Biagi, O. Albano, G.B. Porro, R. Cheli, G. Mazzacca, et al.
Levosulpiride in functional dyspepsia: a multicentric, double-blind, controlled trial.
Ital J Gastroenterol, 28 (1996), pp. 317-323
[185.]
C.W. Song, H.J. Chun, C.D. Kim, H.S. Ryu, J.G. Choe, J.H. Hyun.
Effects of levosulpiride in patients with functional dyspepsia accompanied by delayed gastric emptying.
Korean J Intern Med, 13 (1998), pp. 15-21
[186.]
C. Mansi, P. Borro, M. Giacomini, R. Biagini, M.R. Mele, N. Pandolfo, et al.
Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis.
Aliment Pharmacol Ther, 14 (2000), pp. 561-569
[187.]
B.I. Hallerback, G. Bommelaer, E. Bredberg, M. Campbell, M. Hellblom, K. Lauritsen, et al.
Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study.
Aliment Pharmacol Ther, 5 (2002), pp. 959-967
[188.]
Soo S, Moayyedi P, Deeks J, Delaney B, Lewis M, Forman D. Psychological interventions for non-ulcer dyspepsia (Cochrane Review). En: The Cochrane Library, n.° 3, 2002. Oxford: Update Software
[189.]
J.L. Jackson, P.G. O'Malley, G. Tomkins, E. Baldin, J. Santoro, K. Kroenke.
Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis.
Am J Med, 108 (2000), pp. 65-72
[190.]
E.L. Calvert, L.A. Houghton, P. Cooper, J. Morris, P.J. Whorwell.
Long-term improvement in functional dispepsia using hypnoterapy.
Gastroenterology, 123 (2002), pp. 1.778-1.785
[191.]
R.L. Jaakkimainen, E. Boyle, F. Tudiver.
Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms?.
A meta-analysis BMJ, 319 (1999), pp. 1.040-1.044
[192.]
L. Laine, P. Schoenfeld, M.B. Fennerty.
Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials.
Ann Intern Med, 134 (2001), pp. 361-369
[193.]
J.P. Gisbert, X. Calvet, R. Gabriel, J.M. Pajares.
Infección por Helicobacter pylori y dispepsia funcional. Metaanálisis de la eficacia del tratamiento erradicador.
Med Clin (Barc), 118 (2002), pp. 405-409
[194.]
Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia (Cochrane Review). En: The Cochrane Library, n.° 3, 2002. Oxford: Update Software
[196.]
P.I. Hsu, K.H. Lai, H.H. Tseng, G.H. Lo, C.C. Lo, C.K. Lin, et al.
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Aliment Pharmacol Ther, 15 (2001), pp. 195-201
[197.]
H.R. Koelz, R. Arnold, M. Stolte, M. Fischer, A.L. Blum.
The Frosch Study Group. Treatment of Helicobacter pylori in functional dispepsia resistant to conventional management: a double blind randomised trial with a six month follow up.
Gut, 52 (2003), pp. 40-46
[198.]
R.A. Moore.
Helicobacter pylori and peptic ulcer: a systematic review of effectiveness and an overview of the economic benefits of implementing what is known to be effective.
[199.]
J.G. Penston.
Review article: clinical aspects of Helicobacter pylori eradication therapy in peptic ulcer disease.
Aliment Pharmacol Ther, 10 (1996), pp. 469-486
[200.]
L. Laine, R.J. Hopkins, L.S. Girardi.
Has the impact of Heli-cobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials.
Am J Gastroenterol, 93 (1998), pp. 1.409-1.415
[201.]
Forman D, Bazzoli F, Bennett C, Broutet N, Calvet-Calvo X, Chiba N et al. Therapies for the eradication of Helicobacter pylori (Protocol for a Cochrane Review). En: The Cochrane Library, n.° 4, 2002. Oxford: Update Software
[202.]
B. Delaney, P. Moayyedi, D. Forman.
Helicobacter pylori infection.
Clin Evid, 7 (2002), pp. 414-428
[203.]
C.W. Howden, R.H. Hunt.
Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology.
Am J Gastroenterol, 93 (1998), pp. 2.330-2.338
[204.]
J.P. Gisbert, X. Calvet, F. Gomollón, R. Sainz.
Conferencia de consenso. Tratamiento erradicador de Helicobacter pylori. Recomendaciones de la Conferencia Española de Consenso.
Med Clin (Barc), 114 (2000), pp. 185-195
[205.]
A. Leodolter, M. Kulig, H. Brasch, W. Meyer-Sabellek, S.N. Willich, P. Malfertheiner.
A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pyloriassociated gastric or duodenal ulcer.
Aliment Pharmacol Ther, 15 (2001), pp. 1.949-1.958
[206.]
J.P. Gisbert, D. Boixeda, C.M. de Argila, F. Bermejo, C. Redondo, L. de Rafael.
Erosive duodenitis: prevalence of Helicobacter pylori infection and response to eradication therapy with omeprazole plus two antibiotics.
Eur J Gastroenterol Hepatol, 9 (1997), pp. 957-962
[207.]
A. Shiotani, S. Nishioka, M. Iguchi, K. Yanaoka, K. Okada, H. Tamai, et al.
Duodenal erosions after eradication of Helicobacter pylori infection.
Gastrointest Endosc, 54 (2001), pp. 448-453
[208.]
L. Laine, H. Cohen, R. Sloane, M. Marin-Sorensen, W.M. Weinstein.
Interobserver agreement and predictive value of endoscopic findings for H. pylori and gastritis in normal volunteers.
Gastrointest Endosc, 42 (1995), pp. 420-423
[209.]
A. Vincze, O. Karadi, B. Hunyady, F. Pakodi, G. Suto, G. Mozsik.
One year follow-up of patients after successful Helicobacter pylori eradication therapy.
J Physiol Paris, 95 (2001), pp. 457-460
[210.]
F.S. Lehmann, E.L. Renner, B. Meyer-Wyss, C.H. Wilder-Smith, L. Mazzucchelli, C. Ruchti, et al.
Helicobacter pylori and gastric erosions. Results of a prevalence study in asymptomatic volunteers.
Digestion, 62 (2000), pp. 82-86
[211.]
V. Kate, N. Ananthakrishnan, S. Badrinath, S.K. Amarnath, M. Balamurugan, C. Ratnakar.
Helicobacter pylori infection and erosive gastritis.
J Assoc Physicians India, 46 (1998), pp. 436-437
[212.]
A.S. Taha, R.D. Sturrock, R.I. Russell.
Mucosal erosions in longterm non-steroidal anti-inflammatory drug users: predisposition to ulceration and relation to Helicobacter pylori.
Gut, 36 (1995), pp. 334-336
[213.]
B. Annibale, M. Marignani, B. Monarca, G. Antonelli, A. Marcheggiano, G. Martino, et al.
Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis.
Ann Intern Med, 131 (1999), pp. 668-672
[214.]
S.J. Veldhuyzen van Zanten, P.M. Sherman.
Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview.
CMAJ, 150 (1994), pp. 177-185
[215.]
K.E. McColl.
The role of Helicobacter pylori eradication in the management of acute bleeding peptic ulcer.
Eur J Gastroenterol Hepatol, 7 (1995), pp. 753-755
[216.]
V.K. Sharma, A.V. Sahai, F.A. Corder, C.W. Howden.
Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage.
Aliment Pharmacol Ther, 15 (2001), pp. 1.939-1.947
[217.]
S.M. Buring, L.H. Winner, R.C. Hatton, P.L. Doering.
Discontinuation rates of Helicobacter pylori treatment regimens: a meta-analysis.
Pharmacotherapy, 19 (1999), pp. 324-332
[218.]
J.G. Penston, K.E. McColl.
Eradication of Helicobacter pylori: an objective assessment of current therapies.
Br J Clin Pharmacol, 43 (1997), pp. 223-243
[219.]
R.J. Laheij, L.G. Rossum, J.B. Jansen, H. Straatman, A.L. Verbeek.
Evaluation of treatment regimens to cure Helicobacter pylori infection -a meta-analysis.
Aliment Pharmacol Ther, 13 (1999), pp. 857-864
[220.]
T. Lind, S. Veldhuyzen van Zanten, P. Unge, R. Spiller, E. Bayerdorffer, C. O'Morain, et al.
Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study.
Helicobacter, 1 (1996), pp. 138-144
[221.]
H. Miwa, R. Ohkura, T. Murai, K. Sato, A. Nagahara, S. Hirai, et al.
Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.
Aliment Pharmacol Ther, 13 (1999), pp. 741-746
[222.]
B.C. Wong, W.M. Wong, Y.K. Yee, W.K. Hung, A.W. Yip, M.L. Szeto, et al.
Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection.
Aliment Pharmacol Ther, 15 (2001), pp. 1.959-1.965
[223.]
K. Murakami, R. Sato, T. Okimoto, M. Nasu, T. Fujioka, M. Kodama, et al.
Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin.
Aliment Pharmacol Ther, 16 (2002), pp. 1.933-1.938
[224.]
S. Veldhuyzen Van Zanten, K. Lauritsen, J.C. Delchier, J. Labenz, C.M. De Argila, T. Lind, et al.
One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease.
Aliment Pharmacol Ther, 14 (2000), pp. 1.605-1.611
[225.]
Z. Tulassay, A. Kryszewski, P. Dite, D. Kleczkowski, J. Rudzinski, Z. Bartuzi, et al.
One week of treatment with esomeprazolebased triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease.
Eur J Gastroenterol Hepatol, 13 (2001), pp. 1.457-1.465
[226.]
L. Laine.
Esomeprazole in the treatment of Helicobacter pylori.
Aliment Pharmacol Ther, 16 (2002), pp. 115-118
[227.]
C.H. Schmid, G. Whiting, D. Cory, S.D. Ross, T.C. Chalmers.
Omeprazole plus antibiotics in the eradication of Helicobacter pylori infection: a meta-regression analysis of randomized, controlled trials.
Am J Ther, 6 (1999), pp. 25-36
[228.]
L.A. Fischbach, K.J. Goodman, M. Feldman, C. Aragaki.
Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis.
Int J Epidemiol, 31 (2002), pp. 128-139
[229.]
Jovell AJ, Aymerich M, García-Altés A, Serra-Prat M. Guia de pràctica clínica del tractament erradicador de la infecció per Helicobacter pylori associada a l'úlcera duodenal en l’atenció primària. Barcelona: Agència d'Avaluació de Tecnologia Mèdica. Servei Català de la Salut. Departament de Sanitat i Seguretat Social. Generalitat de Catalunya: setembre de 1998
[230.]
J. Huang, R.H. Hunt.
The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole.
Aliment Pharmacol Ther, 13 (1999), pp. 719-729
[231.]
J.P. Gisbert, J.M. Pajares.
Resistencia de Helicobacter pylori al metronidazol y a la claritromicina en España. Una revisión sistemática.
Med Clin (Barc), 116 (2001), pp. 111-116
[232.]
E. Cuchí, M. Forné, S. Quintana, J. Lite, J. Garau.
Evolución de la sensibilidad de 235 cepas de Helicobacter pylori entre 1995 y 1998 e impacto del tratamiento antibiótico.
Enferm Infecc Microbiol Clin, 20 (2002), pp. 157-160
[233.]
J.P. Gisbert, X. Calvet, L. Bujanda.
Usefulness of 14-day rifabutin, amoxicillin and omeprazole triple therapy as a rescue therapy after multiple treatment failures.
Helicobacter, (2003),
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos